Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation: phase II study evaluation of multimodality treatment for locally advanced cervical cancer

Sailendra Narayan Parida, Lal Mohan Soy, Biswa Ranjan Routroy, Sugyan Nandan Mohanty.




Abstract
Cited by 0 Articles

Aim: In order to treat locally advanced cervical carcinoma, our goal was to assess the effectiveness and safety of neoadjuvant chemotherapy, radical hysterectomy, postoperative radiation, and biweekly cisplatin. Materials and Method: Radical type III hysterectomy, adjuvant radiation therapy, and 6-weekly doses of cisplatin at 35 mg/m2 were given to 40 patients staged as IB2-IIIB over the period of three 20-day courses of carboplatin (area under the time plot: 5 mg/min/ml) and paclitaxel (at 170 mg/m2 by 2-h infusion both on day 2). Evaluations were made of response rate, resectability, toxicity, and lifespan. Result: There were 40 patients enrolled. Each was assessed for toxicity and responsiveness to neoadjuvant chemotherapy. 100 courses in total were given out. 94% of patients had clinical responses, with a 94% confidence range (CI) of 89.1% to 99%. 8% of the work is finished, while 85% is incomplete. The pathologically complete or nearly complete responses were observed in 16% and 19% of the 40 patients who underwent surgery (resectability: 94%); positive surgical boundaries were identified in 11% of the patients, and positive pelvic lymph nodes were seen in 19% of the patients. Adjuvant chemoradiation was scheduled for 25 patients. A median of 4 cisplatin treatments were administered together with a mean dose of 49.2 Gy over the course of 42.7 days (range, 32–60). The average brachytherapy dose was 30 Gy (range 25.4–35.4). Neutropenia grades 3 and 4 were well tolerated with neoadjuvant therapy in 11% and 2% of the courses, respectively. Adjuvant chemoradiation generally caused grade 1/2 haematological and gastrointestinal toxicity. 35 patients in all completed the entire course of therapy. The estimated overall survival in the intention-to-treat study was 78% (94% CI 61% to 87%) at a median follow-up of 20 months (range 2–25). Neutropenia grades 3 and 4 were well tolerated with neoadjuvant therapy in 11% and 2% of the courses, respectively. Adjuvant chemoradiation generally caused grade 1/2 haematological and gastrointestinal toxicity. Thirty patients in total received the full course of therapy. The estimated overall mortality in the purpose study was 78% (94% CI 61% to 87%) at a median follow-up of 20 months (range 2–25). Conclusion: The combination of neoadjuvant chemotherapy, radical hysterectomy, and adjuvant radiotherapy in addition to cisplatin is a highly effective and tolerable approach for locally advanced cervical cancer.

Key words: cervical carcinoma, neoadjuvant chemotherapy, concomitant chemoradiation, radical hysterectomy






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.